We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Emerging Technologies Boost European IVD Markets

By Labmedica staff writers
Posted on 07 Nov 2006
The emergence and widening adoption of new technologies are boosting the revenue prospects of European in vitro diagnostics (IVD) markets.

Frost & Sullivan (Palo Alto, CA, USA), a global growth-consulting company, reported that the European IVD markets earned revenues of U.S.$6.60 billion in 2005 and estimates they will reach U.S.$9.95 billion in 2012.

"The adoption of new technologies, such as molecular and point-of-care testing, combined with the increasing trend towards laboratory automation will drive growth in the European IVD markets,” noted Frost & Sullivan research associate A.K. More...
Arun. "An emphasis on providing high quality healthcare and ensuring timely diagnosis is driving the adoption of these clinical tests and automated solutions while promoting market growth.”

Emerging markets such as molecular testing and near testing are supporting established segments such as clinical chemistry and hematology, thereby spurring market expansion. Moreover, labor shortages are pressurizing clinical laboratories to adopt high throughput and modular solutions, reinforcing growth in the market.

However, challenges still exist in the industry. Demographic changes combined with new diseases are compelling IVD manufacturers to increase their R&D investments. At the same time, competition has led to price erosion, squeezing revenue returns for market participants. In addition, the growing popularity of emerging segments could overshadow mature segments in the market.

A focused strategy will be vital for IVD manufacturers to ensure sufficient returns on investment. In the present market scenario, approaches centering on competitive pricing, new and innovative products, a broad product portfolio, and novel technologies will allow companies to gain a competitive edge.



Related Links:
Frost & Sullivan

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automatic CLIA Analyzer
Shine i6000
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.